- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04876781
Korean Post-marketing Surveillance for Xeljanz XR (XRPMS)
Korean Post-marketing Surveillance for Xeljanz XR (Registered)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a open-label, non-comparative, non-interventional, prospective, and multi-center study to further evaluate the safety and effectiveness of Xeljianz XR in routine clinical practice in Korea.
Safety is the primary interest of this study, which will be assessed based on adverse events (AEs) that occur during the 6 months from the first dose of Xeljanz XR. The efficacy endpoints will be the modified Disease Activity Score using 28 joint counts (DAS28) change from baseline, European League Against Rheumatism (EULAR) response, and American College of Rheumatology 20% improvement criteria (ACR20) response after treatment.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Pfizer CT.gov Call Center
- Phone Number: 1-800-718-1021
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Pfizer
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
Xeljanz® XR is administered according to indications on the approved labeling
- Treatment of moderate to severe active RA in adult patients (18 years of age or older) who have had an inadequate response or are intolerant to methotrexate
- In combination with methotrexate, treatment of active psoriatic arthritis (PsA) in adult patients (18 years of age or older) who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
- Treatment of active ankylosing spondylitis (AS) in adult patients (18 years of age or older) who have responded inadequately to conventional therapy
- In the following patients, Xeljanz® XR should be used only for patients who have had an inadequate response or are intolerant to the existing treatment.
A. Patients aged 65 or older B. Cardiovascular high-risk patients C. Patients at risk for malignancy
- Patients who have previously been given Xeljanz 5mg, who have changed Xeljanz® XR, are also eligible for registration in the study
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
Exclusion Criteria:
Patients meeting any of the following criteria will not be included in the study:
- Patients with a history of hypersensitivity to any ingredients of this product.
- Patients with serious infection (sepsis, etc.) or active infection including localized infection.
- Patients with active tuberculosis.
- Patients with severe hepatic function disorder.
- Patients with an absolute neutrophil count (ANC) <1,000 cells/mm3. *
- Patients with a lymphocyte count <500 cells/mm3. *
- Patients with a hemoglobin level <9 g/dL. *
- Pregnant or possibly pregnant women. * Do not initiate Xeljanz XR in the following cases: ANC; absolute neutrophil count <1,000 cells/mm3 ALC; absolute lymphocyte count <500 cells/mm3 Hemoglobin<9 g/dL
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events (AEs)
Time Frame: Maximum of 52 weeks from the time of initial administration of Xeljanz XR
|
AE is any untoward medical occurrence attributed to study drug in a participant who received study drug.
Serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent are events between first dose of study drug and up to end of this PMS after last dose that were absent before treatment or that worsened relative to pretreatment state.
Relatedness to Xeljanz XR was assessed by the investigator (Yes/No).
Participants with multiple occurrences of an AE within a category were counted once within the category.
|
Maximum of 52 weeks from the time of initial administration of Xeljanz XR
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in Disease Activity Score based on 28-joints Count (DAS28)
Time Frame: Baseline, 52 weeks after treatment or within 30 days after last dose of medicinal product
|
DAS28, a modified version of the original Disease Activity Score (DAS), is a quantitative measure of disease activity used to monitor the treatment of RA.
|
Baseline, 52 weeks after treatment or within 30 days after last dose of medicinal product
|
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
Time Frame: Baseline, 52 weeks after treatment or within 30 days after last dose of medicinal product
|
The Disease Activity Score Based on 28-joints Count based (DAS28-based) EULAR response criteria is used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached.
|
Baseline, 52 weeks after treatment or within 30 days after last dose of medicinal product
|
Number of Participants With an American College of Rheumatology 20% (ACR20) Response
Time Frame: Baseline, 52 weeks after treatment or within 30 days after last dose of medicinal product
|
ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
|
Baseline, 52 weeks after treatment or within 30 days after last dose of medicinal product
|
Assessment of Ankylosing Spondylitis response (ASAS20)
Time Frame: Baseline, 52 weeks after treatment or within 30 days after last dose of medicinal product
|
The ASAS Response Criteria (ASAS 20) is defined as an improvement of at least 20% and an absolute improvement of at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function (BASFI), and Inflammation (last 2 questions of BASDAI).
|
Baseline, 52 weeks after treatment or within 30 days after last dose of medicinal product
|
Changes from baseline in the number of tender joints and swollen joints
Time Frame: Baseline, 52 weeks after treatment or within 30 days after last dose of medicinal product
|
The number of tender joints and swollen joints, which are the specific components of the ACR20 response, are measured.
The improvement from baseline after treatment is assessed.
|
Baseline, 52 weeks after treatment or within 30 days after last dose of medicinal product
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Joint Diseases
- Musculoskeletal Diseases
- Skin Diseases, Papulosquamous
- Spinal Diseases
- Bone Diseases
- Spondylarthropathies
- Spondylarthritis
- Psoriasis
- Bone Diseases, Infectious
- Ankylosis
- Axial Spondyloarthritis
- Arthritis
- Arthritis, Psoriatic
- Spondylitis
- Spondylitis, Ankylosing
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Janus Kinase Inhibitors
- Tofacitinib
Other Study ID Numbers
- A3921369
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Active Psoriatic Arthritis
-
Sun Pharmaceutical Industries LimitedActive, not recruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
-
Sun Pharmaceutical Industries LimitedCompleted
-
Bristol-Myers SquibbCompletedActive Psoriatic ArthritisSpain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
-
Sun Pharmaceutical Industries LimitedRecruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Estonia, Korea, Republic of, Poland, Slovakia, Spain, Taiwan, Germany, Italy, India, Canada
-
Innovaderm Research Inc.Ciusss de L'Est de l'Île de MontréalWithdrawnPsoriasis Vulgaris | Active Psoriatic Arthritis
-
UCB Biopharma S.P.R.L.CompletedModerate and Severe Active Rheumatoid Arthritis | Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Moderately to Severely Active Crohn's DiseaseUnited States
-
AmgenRecruitingActive Juvenile Psoriatic ArthritisSpain, United Kingdom, Turkey, Belgium, France, Greece, Italy, Austria, Germany, Netherlands, Poland, Portugal, Romania, Lithuania, South Africa
-
Universitätsklinikum Hamburg-EppendorfBristol-Myers Squibb; Eli Lilly and Company; UCB Pharma; Merck Sharp & Dohme LLC; AbbVi... and other collaboratorsRecruiting
-
AbbVieActive, not recruitingPsoriatic Arthritis (PsA)United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
-
Bristol-Myers SquibbCompletedPsoriatic Arthritis (PsA)Germany
Clinical Trials on Tofacitinib XR
-
Johns Hopkins UniversityPfizerCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedSystemic Lupus Erythematosus | Cutaneous LupusUnited States
-
PfizerCompletedAnkylosing SpondylitisKorea, Republic of, United States, Spain, Taiwan, Canada, Czech Republic, Poland, Hungary, Germany, Russian Federation
-
PfizerCompleted
-
Eisai Inc.Terminated
-
PfizerCompletedPlaque PsoriasisUnited States
-
PfizerCompleted
-
Nanfang Hospital of Southern Medical UniversityJiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruitingRheumatoid Arthritis